2-氯甲基-4,6-二氯嘧啶 | 19875-05-9

• 物质功能分类: 医药中间体 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 2-氯甲基-4,6-二氯嘧啶
• 中文别名: 4,6-二氯-2-(氯甲基)嘧啶
• 英文名称: 4,6-dichloro-2-(chloromethyl)pyrimidine
• 英文别名: 4,6-Dichlor-2-chlor-methyl-pyrimidin
• CAS: 19875-05-9
• 化学式: C₅H₃Cl₃N₂
• 分子量: 197.451
• InChiKey: OGXCXLWVUKSJGE-UHFFFAOYSA-N

物化性质

• 熔点：
  45 °C
• 沸点：
  114 °C(Press: 15 Torr)
• 密度：
  1.548±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2933599090
• 包装等级：
  II
• 危险类别：
  8
• 危险性防范说明：
  P501,P260,P270,P264,P280,P303+P361+P353,P301+P330+P331,P363,P301+P312+P330,P304+P340+P310,P305+P351+P338+P310,P405
• 危险品运输编号：
  1759
• 危险性描述：
  H302,H314
• 储存条件：
  2-8°C

反应信息

• 作为反应物：
  描述：

  2-氯甲基-4,6-二氯嘧啶 在 sodium iodide 作用下， 以 丙酮 为溶剂， 反应 3.0h， 以93%的产率得到4,6-dichloro-2-iodomethylpyrimidine
  参考文献：
  名称：

  [EN] SUBSTITUTED NITROGEN-CONTAINING SIX-MEMBERED AMINO-HETEROCYCLES AS VANILLOID-1 RECEPTOR ANTAGONISTS FOR TREATING PAIN
  [FR] UTILISATION D'HETEROCYCLES AMINES A SIX ELEMENTS CONTENANT DE L'AZOTE SUBSTITUES COMME ANTAGONISTES DU RECEPTEUR VANILLOIDE DE TYPE 1 POUR LE TRAITEMENT DE LA DOULEUR

  摘要：

  本发明提供了一种化合物，其化学式为（I）：Y-J-NH-Z，其中：Y为喹啉或异喹啉，可选地取代为一个或两个从羟基、卤素、卤代C1-4烷基、C1-4烷基、C1-4烷氧基、卤代C1-4烷氧基、硝基和氨基中独立选择的取代基；J为吡啶、吡啶嗪、吡嗪、嘧啶或三嗪，可选地取代为一个或两个从羟基、卤素、卤代C1-4烷基、C1-4烷基、C3-5环烷基、C1-4烷氧基、羟基C1-4烷基、氰基、羟基、C1-4环烷氧基、C1-4烷基硫氧基、卤代C1-4烷氧基、硝基、Q、（CH2）pQ、NR2R3、-（CH2）pNR2R3和-O（CH2）pNR2R3中独立选择的取代基；其中J在相对于NH和Y的位置上被取代；Z为苯基或吡啶基，可选地取代为一个或两个从卤素、卤代C1-4烷基、C1-4烷基、C1-4烷氧基、卤代C1-4烷氧基、硝基和氨基中独立选择的取代基；Q为苯基，含有一个、两个、三个或四个从O、N和S中选择的杂原子的五元杂环，最多一个杂原子为O或S，或含有一个、两个或三个氮原子的六元杂环，可选地取代为C1-4烷基；每个R2和R3从H和C1-4烷基中选择，或R2和R3，连同它们连接的氮原子，可形成一个含有氧原子或进一步氮原子的六元环，该环可选地取代为C1-4烷基或Q；p为1、2或3；或其药学上可接受的盐；包含它的药物组合物；其在治疗方法中的使用；用于制造药物的使用；以及使用它治疗需要VR1拮抗剂（如疼痛、咳嗽、胃食管反流病和抑郁症）的疾病的方法。

  公开号：

  WO2005047279A1
• 作为产物：
  描述：

  6-羟基-2-(羟基甲基)-4(3h)-嘧啶酮 在 三氯氧磷 作用下， 以72%的产率得到2-氯甲基-4,6-二氯嘧啶
  参考文献：
  名称：

  Chloroalkylpyrimidines: Synthesis and properties

  摘要：

  DOI：

  10.1007/bf02465841

文献信息

• [EN] NEW MACROCYCLIC LRRK2 KINASE INHIBITORS<br/>[FR] NOUVEAUX INHIBITEURS MACROCYCLIQUES DE LA LRRK2 KINASE
  申请人：SERVIER LAB

  公开号：WO2021224320A1

  公开（公告）日：2021-11-11

  Compounds of formula (I): wherein R, X1, X2, X3, Z1, Z2, Z3, A and Ra are as defined in the description. Medicaments.

  式(I)的化合物：其中R、X1、X2、X3、Z1、Z2、Z3、A和Ra的定义如描述中所述。药物。
• Discovery of 2-[(&lt;i&gt;E&lt;/i&gt;)-2-(7-Fluoro-3-methylquinoxalin-2-yl)vinyl]-6-pyrrolidin-1-yl-&lt;i&gt;N&lt;/i&gt;-(tetrahydro-2&lt;i&gt;H&lt;/i&gt;-pyran-4-yl)pyrimidin-4-amine Hydrochloride as a Highly Selective PDE10A Inhibitor
  作者：Yoichi Kadoh、Haruko Miyoshi、Takehiko Matsumura、Yoshihito Tanaka、Mitsuya Hongu、Mayumi Kimura、Kei Takedomi、Kenji Omori、Jun Kotera、Takashi Sasaki、Tamaki Kobayashi、Hiroyuki Taniguchi、Yumi Watanabe、Koki Kojima、Toshiaki Sakamoto、Toshiyuki Himiyama、Eiji Kawanishi

  DOI：10.1248/cpb.c17-00783

  日期：——

  Phosphodiesterase (PDE) 10A is a dual hydrolase of cAMP and cGMP and highly expressed in striatal medium spiny neurons. Inhibition of PDE10A modulates the activity of medium spiny neurons (MSN) via the regulation of cAMP and cGMP. Signal control of MSN is considered associated with psychotic symptoms. Therefore PDE10A inhibitor is expected as a therapeutic method for psychosis disease such as schizophrenia. Avanafil (1) is a PDE5 inhibitor (treatment for erectile dysfunction) discovered by our company. We paid attention to the homology of PDE10A and PDE5 and took advantage of PDE5 inhibitor library to discover PDE10A inhibitors, and found a series of compounds that exhibit higher potency for PDE10A than PDE5. We transformed the afforded derivatives, which had weak inhibitory activity against PDE10A, and discovered stilbene as a PDE10A inhibitor. Brain penetration of this compound was improved by further conversion of N-containing heterocycles and their substituents. The afforded dimethylaminopyrimidine was effective for rat conditioned avoidance response (CAR) test; however, it did not exhibit good brain penetration. We performed in-depth optimization focusing on substituents of the quinoxaline ring, and produced 3-methyl-7-fluoro quinoxaline. This compound was the most effective in rat CAR test due to its strong PDE10A inhibitory activity and good pharmacokinetics.

  磷酸二酯酶（PDE）10A是一种双水解酶，能够水解cAMP和cGMP，并且在纹状体中型棘突神经元中高度表达。抑制PDE10A通过调节cAMP和cGMP调控中型棘突神经元（MSN）的活性。MSN的信号控制被认为与精神症状相关。因此，PDE10A抑制剂被期待作为治疗精神疾病（如精神分裂症）的方法。阿伐那非（1）是我们公司发现的一种PDE5抑制剂（用于治疗勃起功能障碍）。我们关注PDE10A与PDE5的同源性，并利用PDE5抑制剂库发现PDE10A抑制剂，找到了系列对PDE10A表现出比PDE5更高效能的化合物。我们转化了这些对PDE10A抑制活性较弱的衍生物，并发现了白藜芦醇作为PDE10A抑制剂。通过进一步转化含氮杂环及其取代基，改善了该化合物的脑部穿透能力。所得到的二甲氨基嘧啶在大鼠条件回避反应（CAR）测试中显示有效，但脑部穿透性并不好。我们对此进行了深入优化，重点关注喹啉环的取代基，合成了3-甲基-7-氟喹啉。由于其强大的PDE10A抑制活性和良好的药代动力学，该化合物在大鼠CAR测试中是最有效的。
• [EN] AROMATIC NITROGEN-CONTAINING 6-MEMBERED RING COMPOUNDS AND THEIR USE<br/>[FR] COMPOSÉS CYCLIQUES AROMATIQUES AZOTÉS À 6 CHAÎNONS ET LEUR UTILISATION
  申请人：MITSUBISHI TANABE PHARMA CORP

  公开号：WO2010030027A1

  公开（公告）日：2010-03-18

  The present invention provides aromatic nitrogen-containing 6-membered ring compounds having execellent PDE10 inhibitory activity. The present invention relates to an aromatic nitrogen-containing 6-membered ring compound represented by the following formula [I0] or a pharmaceutically acceptable salt thereof, a method for preparing the same, and use of said compounds for PDE10 inhibitors, and a pharmaceutical composition comprising said compounds as an active ingredient: Formula [I0] wherein: X1, X2 and X3 each independently are N or CH, and at least two of X1, X2 and X3 are N; A is *-CH=CH-, *-C(Alk)=CH-, *-CH2-CH2- or *-O-CH2- (* is a bond with R1); Alk is a lower alkyl group; Ring B is an optionally substituted nitrogen-containing aliphatic heterocyclic group; R1 is an optionally substituted nitrogen-containing heterocyclic group, a nitrogen-containing heterocyclic moiety of which is a moiety selected from the group consisting of quinoxalinyl, quinolyl, isoquinolyl, quinazolinyl, pyrazinyl, pyrimidinyl and a moiety thereof fused with a 5 to 6-membered aliphatic ring thereto; Y0 is a group selected from the group consisting of the following (1) to (5): (1) an optionally substituted phenyl or an optionally substituted aromatic monocyclic 5 to 6-membered heterocyclic group; (2) an optionally substituted aminocarbonyl; (3) an optionally substituted amino lower alkyl; (4) -O-R2 wherein R2 is hydrogen, an optionally substituted lower alkyl, lower cycloalkyl, aliphatic monocyclic 5 to 6-membered heterocyclic group, or Formula [AA]; (5) mono- or di-substituted amino; provided that, when Y0 is mono- or di-substituted amino, the nitrogen-containing heterocyclic moiety of R1 is not quinoxalinyl or quinolyl.

  本发明提供了具有出色的PDE10抑制活性的芳香氮含6元环化合物。本发明涉及以下式[I0]所代表的芳香氮含6元环化合物或其药学上可接受的盐，其制备方法，以及将所述化合物用作PDE10抑制剂，以及包含所述化合物作为活性成分的药物组合物：式[I0]其中：X1、X2和X3各自独立地为N或CH，并且至少两个X1、X2和X3为N；A为*-CH=CH-，*-C(Alk)=CH-，*-CH2- -或*-O- -（*为与R1的键）；Alk为低碳烷基基团；环B为可选择取代的含氮脂肪杂环基团；R1为可选择取代的含氮杂环基团，其中的氮杂环基团为从喹喔啉基，喹啉基，异喹啉基，喹唑啉基，吡嗪基，嘧啶基中选取的基团，或者与其中的5至6元脂环融合的基团；Y0为从以下（1）到（5）组成的基团：（1）可选择取代的苯基或可选择取代的芳香单环5至6元杂环基团；（2）可选择取代的氨基羰基；（3）可选择取代的氨基低碳烷基；（4）-O-R2其中R2为氢，可选择取代的低碳烷基，低环烷基，脂肪单环5至6元杂环基团，或式[AA]；（5）单取代或双取代氨基；但是，当Y0为单取代或双取代氨基时，R1的含氮杂环基团不是喹喔啉基或喹啉基。
• TRI-SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS
  申请人：Kawanishi Eiji

  公开号：US20110160206A1

  公开（公告）日：2011-06-30

  The present invention provides a tri-substituted pyrimidine compound having an excellent PDE10 inhibitory activity. The present invention relates to a tri-substituted pyrimidine compound represented by the following formula [I 0 ] or a pharmaceutically acceptable salt thereof, a method for preparing the same, and use of said compound for PDE10 inhibitor, and a pharmaceutical composition comprising said compounds as an active ingredient: wherein: either one of X 1 and X 2 is N, and the other of X 1 and X 2 is CH; A is *-CH═CH—, *-C(Alk)=CH—, *-CH 2 —CH 2 — or *-O—CH 2 — (* is a bond with R 1 ); Alk is a lower alkyl group; Ring B is an optionally substituted nitrogen-containing aliphatic heterocyclic group; R 1 is an optionally substituted quinoxalinyl or an optionally substituted quinolyl; Y 0 is mono- or di-substituted amino group, or a pharmaceutically acceptable salt thereof.

  本发明提供了一种具有优异的PDE10抑制活性的三取代嘧啶化合物。本发明涉及一种由以下式[I0]表示的三取代嘧啶化合物或其药学上可接受的盐，以及制备该化合物的方法，以及将所述化合物用作PDE10抑制剂的用途，以及包含所述化合物作为活性成分的药物组合物：其中：X1和X2中的任一者为N，另一者为CH；A为*-CH═CH—，*-C(Alk)=CH—，*-CH2— —或*-O— —（*是与R1形成键）；Alk为较低的烷基基团；环B为可选择地取代的含氮脂肪杂环基团；R1为可选择地取代的喹唑啉基或可选择地取代的喝啉基；Y0为单取代或双取代的氨基团，或其药学上可接受的盐。
• [EN] N-PYRIMIDINYL HYDROXY PYRAZOLE DERIVATIVES AND USES THEREOF<br/>[FR] DÉRIVÉS D'HYDROXY PYRAZOLE N-PYRIMIDINYLE ET UTILISATIONS ASSOCIÉES
  申请人：CADO BIOTECHNOLOGY IVS

  公开号：WO2019141957A1

  公开（公告）日：2019-07-25

  There is provided herein a compound of formula (I) or a pharmaceutically acceptable salt and/or prodrug thereof, for use in the treatment or prevention of a fungal or bacterial infection wherein R1 to R5 have meanings provided in the description. There is also provided certain compounds and methods for preparating the same.

  本文提供了一种式子（I）的化合物或其药学上可接受的盐和/或前药，用于治疗或预防真菌或细菌感染，其中R1至R5的含义在说明中提供。还提供了某些化合物和制备它们的方法。